Radionuclide Therapy for Skin Malignancies
Skin cancer is the most common human malignancy. Basal cell carcinoma (BCC) and squamous cell carcinoma (SCC) constitute approximately over 95 % (80 and 16 %, respectively) of new cases of non-melanoma skin cancers. It is estimated that over 1.3 million non-melanoma skin cancers will develop annually in the United States (Neville et al. 2007). Moreover, there are many conditions, especially actinic keratosis (AK) and Bowen’s disease, which can progress to invasive SCC. Treatment methods depend on the various clinical indications and histopathology of the malignancy. The three major therapeutic methods are topical application of chemotherapeutic agents, radiotherapy, and surgical management (Bolognia et al. 2003; Fitzpatrick et al. 2008). In this chapter, conventional therapeutic modalities for skin cancer managements will be briefly discussed and a new treatment modality using various beta-emitting radionuclides will be introduced.
KeywordsSquamous Cell Carcinoma Basal Cell Carcinoma Actinic Keratosis Actinic Keratosis Lesion Superficial Basal Cell Carcinoma
- Bolognia J, Jorizzo J, Rapini R (2003) Dermatology. Mosby, LondonGoogle Scholar
- Drake LA, Dinehart SM, Goltz RW et al (1995) Guidelines of care for Mohs micrographic surgery. J Am Acad Dermatol 33(2 Pt 1):271–278Google Scholar
- Duncan KO, Leffell DJ (2003) Dermatology in general medicine, 6th edn. McGraw-Hill, New YorkGoogle Scholar
- Fitzpatrick T, Eisen A, Wolff K, Freedberg I, Austen K (2008) Dermatology in general medicine. McGraw-Hill, New YorkGoogle Scholar
- Rajpar S, Marsden J (2008) ABC of skin cancer. Malden, Blackwell PublishingGoogle Scholar